Combino Pharm: Memantine, a New Business Opportunity
Combino Pharm presents a new business opportunity with the product Memantine.
1. Product Description: memantine hydrochloride
2. Therapeutical indication: treatment of patients with moderate to severe Alzheimer’s disease.
3. Presentation: film-coated tablets of 10mg.
- FDF produced in our manufacturing facility in Malta
- DCP slot in DE available in May 2012
5. Patent status: European alzheimer use patent until 14/04/2014.
6. Regulatory details:
- API Supplier: EU
- DF: Combino Pharm Malta
7. Regulatory Strategy: dossier completed and submission in May 2012 as a national procedure in PT.